TP53 and therapy-related myeloid neoplasm: Given the well-known role of the TP53 mutation in t-MN pathogenesis, we then investigated this mutation: patients who were TP53wt at t0 developed no new mutations at t-MN diagnosis in 29% of cases, 1 new mutation in 29% of cases and 2 new mutations in 25% of cases.